Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S14, 2019. DOI: 10.25251/skin.3.supp.14. Disponível em: https://skin.dermsquared.com/skin/article/view/741. Acesso em: 19 apr. 2025.